Related Experiment Video

Updated: Aug 15, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

[Calcium channel blocker and cardiac hypertrophy]

Toshihiro Takeda1, Kinya Otsu, Masatsugu Hori

  • 1Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.

Clinical Calcium
|October 4, 2005
PubMed

Insights

Long-acting calcium channel blockers effectively reduce left ventricular hypertrophy in hypertensive patients, unlike their short-acting counterparts. Further research is needed to understand the mechanisms behind this cardiovascular benefit.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Context:

  • Hypertension is a prevalent condition often managed with calcium channel blockers.
  • Cardiac hypertrophy is a significant independent risk factor for cardiovascular morbidity and mortality.
  • Current hypertension guidelines recommend specific drug classes for patients with cardiac hypertrophy.

Purpose:

  • To evaluate the differential effects of long-acting versus short-acting calcium channel blockers on left ventricular hypertrophy regression.
  • To compare the efficacy of calcium channel blockers with other recommended antihypertensive agents in patients with cardiac hypertrophy.

Summary:

  • Long-acting calcium channel blockers demonstrated moderately beneficial effects on left ventricular hypertrophy regression, which were statistically indistinguishable from other treatments.
  • Short-acting calcium channel blockers did not show similar benefits in reducing left ventricular hypertrophy.
  • The Japanese Society of Hypertension Guidelines (2004) suggest angiotensin II receptor blockers, ACE inhibitors, or calcium channel blockers for hypertensive patients with cardiac hypertrophy.

Impact:

  • Identifies long-acting calcium channel blockers as a potentially effective therapeutic option for managing cardiac hypertrophy in hypertension.
  • Highlights the need for further investigation into the molecular mechanisms by which calcium channel blockers influence cardiac hypertrophy.
  • Provides evidence to inform clinical practice and guideline development for hypertension management in patients with cardiac hypertrophy.

More Related Videos

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...